Title :

Impact of pharmaceutical care integrated at a psychosocial intervention to reduce caregiver's burden in Alzheimer's disease or related dementias: Negative results at 18 months and difficulties to conduct PHARMAID RCT.

Author(s) :

Novais, T. [Auteur]
Qassemi, S. [Auteur]
Cestac, P. [Auteur]
Mccambridge, C. [Auteur]
Villars, H. [Auteur]
Zueras, A. [Auteur]
Décaudin, Bertrand [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Dambrine, M. [Auteur]
Huvent-Grelle, D. [Auteur]
Roche, J. [Auteur]
Schoenenburg, S. [Auteur]
Federico, D. [Auteur]
Nier, A. C. [Auteur]
Krolak-Salmon, P. [Auteur]
Mouchoux, C. [Auteur]

Journal title :

Contemporary Clinical Trials Communications

Abbreviated title :

Contemp Clin Trials Commun

Volume number :

33

Pages :

101146

Publisher :

Elsevier

Publication date :

2023-07-06

ISSN :

2451-8654

English keyword(s) :

Pharmaceutical care
Psychosocial intervention
Caregivers
Burden
Alzheimer 's disease and related dementias
Negative results

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Background Psychosocial interventions for caregivers of patients with Alzheimer disease and relative dementias (ADRD) reported a caregiver burden improvement. Multicomponent intervention integrating pharmaceutical care ...
Show more >Background Psychosocial interventions for caregivers of patients with Alzheimer disease and relative dementias (ADRD) reported a caregiver burden improvement. Multicomponent intervention integrating pharmaceutical care has not yet been evaluated while ADRD patients and their caregivers are exposed to high risk of drug-related problems. The PHARMAID study aimed to assess the impact of personalized pharmaceutical care integrated to a psychosocial program on the burden of ADRD caregivers at 18 months. Methods The PHARMAID RCT was conducted between September 2016 and June 2020 [ClinicalTrials.gov: NCT02802371 ]. PHARMAID study planned to enroll 240 dyads, i.e. ADRD patients and caregivers, whose inclusion criteria were: outpatient with mild or major neurocognitive disorders due to ADRD, living at home, receiving support from a family caregiver. Three parallel groups compared a control group with two interventional groups: psychosocial intervention and integrated pharmaceutical care at a psychosocial intervention. The main outcome was the caregiver burden assessed by the Zarit Burden Index (ZBI, score range 0–88) at 18 months. Results Overall, 77 dyads were included (32% of the expected sample size). At 18 months, the mean ZBI scores were 36.7 ± 16.8 in the control group, 30.3 ± 16.3 for the group with psychosocial intervention, and 28.8 ± 14.1 in group with integrated pharmaceutical care at psychosocial intervention. No significant difference was demonstrated between the three groups (p = 0.326). Conclusions The findings suggest that PHARMAID program had no significant impact on caregiver burden at 18 months. Several limitations have been highlighted and discussed by the authors in order to formulate recommendations for further research.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Submission date :

2023-10-20T05:41:23Z
2024-05-15T07:50:31Z